228113-66-4
Chemical Structure
Maralixibat chloride
Synonym(s): SHP625 chloride; LUM001 chloride; Lopixibat chloride
- CAS No.: 228113-66-4
- Formula:C40H56ClN3O4S
- Molecular Weight:710.41
IUPAC Name: 1-(4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium chloride
InChIKey: POMVPJBWDDJCMP-RUKDTIIFSA-M
SMILES: O=S1(CC(CCCC)(CCCC)[C@H](O)[C@H](C2=CC=C(OCC3=CC=C(C[N+]4(CC5)CCN5CC4)C=C3)C=C2)C6=CC(N(C)C)=CC=C61)=O.[Cl-]
Biological Activity: Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Maralixibat chloride | 99.61% | Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Shirley M. Maralixibat: First Approval [published correction appears in Drugs. 2021 Dec 6;:]. Drugs. 2022;82(1):71-76. [Content Brief]
- [2]. Mayo MJ, et al. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatol Commun. 2019 Feb 1;3(3):365-381. [Content Brief]
Keywords
